Barry Simon

Dr. Simon has served as the Company’s President and CEO from 2007 to 2015, as its President and CAO since 2015 and presently serves as a Director and as its CCAO. Dr. Simon also presently serves as Director and Chairman of the Compensation Committee for both Cue BioPharma (NASDAQ: CUE) and Viracta Therapeutics (NASDAQ: VIRX). Previously, Dr. Simon held Vice President, senior level and advisory positions at F. Hoffmann-La Roche (VTX: ROG), Roche Labs, Connetics Corp. (NASDAQ: CNCT), Immunomedics (NASDAQ: IMMU), Immusol, NorthSound Capital, LLC, and HealthPro BioVentures. Dr. Simon has broad experience in the public and private settings, having led product and portfolio divestitures and acquisitions, strategic licensing and joint ventures, as well as numerous commercial product launches, IND & BLA regulatory filings and life cycle management. Dr. Simon worked across several therapeutic areas including oncology, virology, dermatology and on eight products launches. Dr. Simon attended corporate training programs by the London School of Business and the Amos Tuck School of Business at Dartmouth College. Dr. Simon trained clinically in Infectious Diseases, Anesthesiology and Internal Medicine and received his M.D. from the SUNY Downstate, Health Sciences Center in New York.